Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional ...
Brand Name : Iopidine
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for o...
Brand Name : Iopidine
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
Details : IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic solution for topical application to the eye.
Brand Name : Iopidine
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2022
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
Details : FDA-approved IOPIDINE 1% is the gold standard for treating or preventing intraocular pressure during and after YAG laser eye surgery, which is required for about 40% of all prior cataract surgery patients.
Brand Name : Iopidine
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 20, 2021
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Essential Pharma Expands Global Portfolio with Ocular and Postpartum Acquisitions
Details : Essential pharma acquires Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, for the adjunctive treatment of glaucoma and Methergine for treating post-partum haemorrhage.
Brand Name : Iopidine
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 16, 2021
Lead Product(s) : Apraclonidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?